Botaneco Receives Natural Ingredient Approval From ECOCERT(R) for Hydresia(TM) G2

Calgary, Canada (ots/PRNewswire) -

- Hydresia(TM) G2 Approved by leading European Authority on
Natural Organic Certification

TSX symbol: SBS

Botaneco Specialty Ingredients Inc. (Botaneco), a subsidiary of
SemBioSys Genetics Inc. (SemBioSys), today announced that its second
generation oleosome product, Hydresia(TM) G2, has been authorized by
ECOCERT(R) as an approved raw material, complying with the standards
for ecological and organic cosmetics. ECOCERT(R) is one of the
largest organic control and certification organizations in the world
and conducts inspections in over 80 countries. The company's primary
focus is food and food products, cosmetics, detergents, perfumes,
and textiles.

"Botaneco is dedicated to manufacturing its all-natural products
to comply with the highest natural production standards while
eliminating the use of chemicals and synthetics," said Andrew Baum,
president and CEO of Botaneco's parent company, SemBioSys. "The
ECOCERT(R) authorization validates our product and production
process with the most internationally recognized symbol for natural
and organic raw materials."

Hydresia(TM) G2 is a cold-process emulsifying system comprised
of oleosomes, naturally occurring oil reservoirs derived from
safflower seeds. Oleosomes are nature's warehouse, or storage
facility, for the emollient oils, antioxidants and natural moisture
barriers that serve to keep the skin soft, supple and young looking.
Using a proprietary non-solvent aqueous extraction process, these
oleosomes are isolated from the seed fully intact, and when used in
skin care applications can provide lasting protection to the skin.
Hydresia(TM) G2 is a natural, renewable replacement for hydrocarbon
derived petrolatum, mineral oil and non-ionic surfactants.

About Botaneco Specialty Ingredients Inc.

Botaneco is the global developer and marketer of innovative
oleosome- based ingredients to the personal care and OTC topical
markets. As a technologically driven provider of high performance,
proprietary oleosome- based ingredients, Botaneco is committed to
developing innovative ingredients that offer multifunctional,
tangible and documented benefits to both formulators and consumers.
Botaneco's head office and manufacturing facility is located in
Calgary, Canada and its satellite office in Bensalem , PA. More
information is available and can be accessed at www.botaneco.ca.

About SemBioSys Genetics Inc.

With headquarters in Calgary, Alberta, SemBioSys Genetics Inc.
is a biotechnology company developing protein-based pharmaceuticals
for metabolic and cardiovascular diseases. The Company's lead
pharmaceutical candidates are recombinant human insulin to serve the
rapidly expanding global diabetes market and Apo AI, a next
generation cardiovascular drug. In addition to its pharmaceutical
products, SemBioSys is developing a series of non-pharmaceutical
products addressing animal and aquaculture health, nutritional oils
and human topical markets. More information is available and can be
accessed at www.sembiosys.com.

About ECOCERT(R)

ECOCERT(R) is a control and certification organization, whose
activities are governed accordingly by the public authorities and
legislation. Based in Europe, ECOCERT(R) conducts inspections in over
80 countries and is accredited for structure and procedures by
COFRAC (French committee for accreditation), in accordance with
guide standard ISO 65 (EN 45011), which requires independence,
competence and impartiality.

This press release contains certain forward-looking statements,
including, without limitation, statements containing the words
"believe", "may", "plan", "will", "estimate", "continue",
"anticipate", "intend", " expect" and other similar expressions which
constitute "forward-looking information" within the meaning of
applicable Canadian securities laws. Forward-looking statements
reflect the Company's current expectation and assumptions, and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those anticipated. These
forward-looking statements involve risks and uncertainties including,
but not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and pricing,
new product development, uncertainties related to the regulatory
approval process and other risks detailed from time-to-time in the
Company's ongoing filings with the Canadian securities regulatory
authorities which filings can be found at http://www.sedar.com.
Given these risks and uncertainties, readers are cautioned not to
place undue reliance on such forward-looking statements. The Company
undertakes no obligation to publicly update or revise any
forward-looking statements either as a result of new information,
future events or otherwise, except as required by applicable
Canadian securities laws.

For further information: Botaneco Specialty Ingredients Inc.,
Andrew Baum, President and Chief Executive Officer, Phone:
+1-(403)-717-8767, E-mail: [email protected]

Rückfragehinweis:
For further information: Botaneco Specialty Ingredients Inc., Andrew
Baum, President and Chief Executive Officer, Phone:
+1-(403)-717-8767, E-mail: [email protected]

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | PRN

print